Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from Atripla to Biktarvy in HIV-1
NCT03532425Phase 4Terminated
- Sponsor
- University of Alberta
- Start
- Oct 2018
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1), sponsored by University of Alberta. Started Oct 2018; status: terminated.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03532425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03532425.